Zambon and Amneal Receive Positive CHMP Opinion for Parkinson's Disease Treatment Hopledo®
Zambon and Amneal announced a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding their drug Hopledo® for adults with Parkinson’s disease. The approval is based on Phase 3 trial data showing improved motor function compared to existing treatments, potentially expanding treatment options in Europe where over one million people are affected by Parkinson's.
Tickers: $AMRX